Research suggests that the use of GLP-1 receptor agonists may increase the risk of osteoporosis over a five-year period. Studies are exploring the impact of GLP-1 receptor agonist use on long-term musculoskeletal health and orthopaedic surgical outcomes. Some reports indicate a potential link between GLP-1 receptor agonist use and increased osteoporosis risk, although other unrelated topics are also being discussed in separate reports.